IBD affects 3 million individuals in the US alone but the prevalence is expanding globally. The economic burden of IBD in the US is high, with estimates indicating the combined IBD population in the US is expected to incur a lifetime total cost of over $800 billion. Many current IBD treatments lose effectiveness over time and up to 80% of patients with Crohn’s disease and 20% of patients with Ulcerative Colitis require at least one surgical intervention in their lifetime. Scientific evidence suggests diet, lifestyle factors, and mental health are emerging as key contributors to IBD’s pathogenesis but are often outside of the scope of frontline treatment interventions.